SGLT2 inhibitors reduce all‐cause mortality in randomized controlled trials
The present meta‐analysis is aimed at assessing the effects of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors on all‐cause mortality and differences across different trials and molecules of the class.